×
About 1,763 results

ALLMedicine™ Growth Hormone Deficiency Center

Research & Reviews  634 results

Noncontrast MRI Protocol for Selected Pediatric Pituitary Endocrinopathies: A Procedure...
https://doi.org/10.3174/ajnr.A7228
AJNR. American Journal of Neuroradiology; Huang J, Sarma A et. al.

Sep 4th, 2021 - Although many pediatric neuroradiology practices empirically use noncontrast brain and pituitary MR imaging for evaluation of growth hormone deficiency, central precocious puberty, and short stature, there are currently insufficient published data...

Isolated growth hormone deficiency type IA due to a novel GH1 variant: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411534
BMC Medical Genomics; Yang X, Yuan M et. al.

Sep 3rd, 2021 - A case of isolated growth hormone deficiency type IA (IGHD IA) caused by novel compound heterozygous mutation in the GH1 gene was reported in this study, which aimed to provide insights that will benefit future diagnosis and treatment. We analyzed...

Diagnosing Growth Hormone Deficiency: Can a Combined Arginine and Clonidine Stimulation...
https://doi.org/10.1016/j.eprac.2021.08.004
Endocrine Practice : Official Journal of the American Col... Oron T, Krieger A et. al.

Aug 22nd, 2021 - Given the large number of false-positive growth hormone deficiency (GHD) diagnoses from a single growth hormone (GH) stimulation test in children, 2 different pharmacologic tests, performed on separate days or sequentially, are required. This stud...

Advances in differential diagnosis and management of growth hormone deficiency in child...
https://doi.org/10.1038/s41574-021-00539-5 10.1210/er.2009-0008 10.1210/er.2016-1101 10.20945/2359-3997000000192 10.3389/fendo.2018.00035 10.1530/JME-17-0254 10.1530/EC-18-0099 10.1210/jc.2006-0426 10.1002/ajmg.a.20685 10.1210/jc.2009-0779 10.1093/pch/17.9.505a 10.1016/j.jpeds.2012.05.014 10.1159/000499318 10.1111/cen.14264 10.1159/000452150 10.1111/cen.14364 10.1542/peds.2008-0806 10.1210/jc.2008-0509 10.1159/000503783 10.1136/archdischild-2014-307228 10.1210/jcem.82.2.3841 10.1111/j.1365-2265.2011.03988.x 10.1111/j.1365-2265.2006.02676.x 10.1530/acta.0.0910201 10.1111/cen.14337 10.1373/clinchem.2010.150631 10.1016/j.ghir.2011.05.007 10.1530/EJE-16-0105 10.1373/clinchem.2012.188128 10.1007/s00431-014-2406-3 10.1530/EC-20-0347 10.3389/fendo.2019.00638 10.1016/j.ando.2007.08.004 10.1210/jc.2017-00202 10.1016/j.beem.2013.08.010 10.1210/jc.2013-3059 10.6065/apem.2040018.009 10.1515/jpem-2018-0435 10.1210/jc.2004-0812 10.1210/jc.2013-3060 10.1530/EJE-06-0592 10.1111/cen.12849 10.1210/jc.2008-2783 10.1038/nrendo.2010.147 10.1038/newbio230090a0 10.1203/00006450-199411000-00021 10.1210/jcem-62-4-712 10.1210/jcem.74.4.1548341 10.1111/j.1365-2265.2007.03157.x 10.1210/jc.2009-0746 10.1210/jc.2007-0684 10.1530/eje.0.1470755 10.1210/en.2006-0772 10.1530/eje.1.02293 10.1530/EJE-07-0339 10.1507/endocrj.43.Suppl_S27 10.1677/joe.1.06213 10.1210/jc.2009-0833 10.1210/jc.2014-2696 10.1210/jc.2016-2254 10.1210/en.2005-0212 10.1172/JCI25303 10.1210/jc.2009-1327 10.1002/emmm.201303573 10.1002/ajmg.a.61632 10.1210/me.2004-0341 10.1210/jcem.86.9.7828 10.1210/jc.2003-031765 10.1126/science.257.5073.1115 10.1210/jc.2005-1211 10.1007/s11102-020-01078-4 10.1210/jc.2015-2995 10.1210/jc.2016-1095 10.1093/hmg/ddx318 10.1210/jc.2014-1984 10.1038/ejhg.2009.125 10.1016/S0387-7604(86)80075-4 10.1111/j.1365-2265.2009.03572.x 10.1038/477 10.1073/pnas.1503346113 10.1016/j.jpeds.2005.07.031 10.1016/j.eclinm.2019.11.017 10.1016/j.gene.2013.10.043 10.1111/j.1528-1167.2006.00464.x 10.1210/jc.2008-1219 10.1530/EJE-20-1453 10.1210/jc.2018-02316 10.1210/jc.2014-1160 10.1086/344661 10.1086/430134 10.1210/jc.2007-2389 10.1210/jc.2006-2177 10.1093/hmg/ddn114 10.1210/jc.2014-4484 10.1136/jmedgenet-2014-102856 10.1210/jc.2011-0454 10.1073/pnas.2235734100 10.1210/jc.2012-3982 10.1210/clinem/dgz184 10.1530/EC-15-0015 10.1210/jc.2011-2938 10.1053/j.gastro.2013.03.048 10.1111/cen.13094 10.1111/j.1365-2265.2011.04238.x 10.1530/EJE-19-0168 10.1210/jc.2016-3158 10.1159/000350829 10.1016/j.beem.2016.11.008 10.1530/EJE-12-0801 10.1016/j.ebiom.2018.09.026 10.1210/jc.2017-00332 10.1111/cge.13805 10.1111/jcmm.13272 10.1007/s00247-017-3817-x 10.1210/jc.2017-01660 10.1172/jci.insight.134310 10.1007/s00247-005-1512-9 10.1530/EJE-18-0094 10.3174/ajnr.A3959 10.1515/jpem-2018-0272 10.1038/76041 10.1007/s00247-019-04502-5 10.1113/jphysiol.1957.sp005764 10.1002/cne.901350202 10.1159/000180918 10.1210/jcem-73-1-79 10.1002/(SICI)1096-8628(19970331)69:3<235::AID-AJMG4>3.0.CO;2-K 10.1007/BF02072501 10.1007/BF02072226 10.1016/j.clp.2017.11.001 10.1111/j.1365-2265.2009.03554.x 10.1186/s40348-020-00108-2 10.1046/j.1365-2265.1996.00789.x 10.1046/j.1365-2265.2003.01768.x 10.1016/j.beem.2016.11.005 10.20945/2359-3997000000190 10.1210/clinem/dgz149 10.1097/MED.0000000000000416 10.1210/clinem/dgaa049 10.1007/s12020-019-01950-9 10.1210/jc.2007-1581 10.1159/000322878 10.1007/s12020-019-02057-x 10.1210/jc.2008-1503 10.1210/jc.2009-1471 10.1159/000318782 10.1016/j.ghir.2008.08.001 10.1159/000308174 10.1007/s00247-015-3468-8 10.7205/MILMED-D-17-00011 10.1111/j.1651-2227.1998.tb01463.x 10.1002/pbc.24667 10.1210/jc.2011-1995 10.1210/jc.2011-2882 10.1016/S2213-8587(20)30163-7 10.1210/jc.2015-3951 10.1210/er.2018-00166 10.1210/clinem/dgaa089 10.1210/jc.2015-1002 10.1097/MOP.0000000000000505 10.1530/EJE-12-0807 10.1111/j.1365-2265.2012.04473.x 10.4158/GL-2019-0405 10.1210/jcem.87.2.8216 10.1515/JPEM.2006.19.5.691 10.1210/jc.2003-031224 10.1210/er.2013-1067 10.1210/jc.2009-1134 10.1530/EC-20-0491 10.1111/j.1365-2265.2004.01935.x 10.1210/jc.2003-031588 10.1515/jpem-2018-0019 10.1530/EJE-13-0572 10.1530/EJE-12-1083 10.1530/EJE-18-0370 10.1210/jc.2009-1326 10.2337/dc11-0449 10.1210/jc.2011-0448 10.1210/jcem.86.3.7268 10.1016/j.metabol.2008.07.024 10.1001/jamapediatrics.2020.5199 10.1001/jamapediatrics.2020.5232 10.1007/s11154-020-09591-4
Nature Reviews. Endocrinology; Hage C, Gan HW et. al.

Aug 22nd, 2021 - Growth hormone (GH) deficiency (GHD) in children is defined as impaired production of GH by the pituitary gland that results in growth failure. This disease might be congenital or acquired, and occurs in isolation or in the setting of multiple pit...

Growth hormone replacement therapy: is it safe to use in children with asymptomatic pit...
https://doi.org/10.1515/jpem-2021-0479
Journal of Pediatric Endocrinology & Metabolism : JPEM; Sheldon BL, O'Brien MW et. al.

Aug 19th, 2021 - Small pituitary cysts are commonly discovered on pediatric brain magnetic resonance imagings (MRIs), particularly in patients with growth hormone deficiency (GHD). We examined the need for operative management in children with these masses as well...

see more →

Guidelines  1 results

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

see more →

Drugs  14 results see all →

News  55 results

Weight Gain Common in Childhood Brain Tumor Survivors
https://www.medscape.com/viewarticle/947349

Mar 12th, 2021 - Children who have been treated for brain tumors often experience significant weight gain, and new findings suggest that this could be a sign of hypothalamic-pituitary (HP) dysfunction. "We believe that endocrine surveillance should be initiated ea...

FDA OKs Somapacitan (Sogroya), First Once-Weekly Growth Hormone
https://www.medscape.com/viewarticle/936834

Sep 3rd, 2020 - The US Food and Drug Administration (FDA) has approved somapacitan (Sogroya, Novo Nordisk) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).  Somapacitan is a human growth hormone analog. It is admini...

FDA OKs Somapacitan (Sogroya), First Once-Weekly Growth Hormone
https://www.staging.medscape.com/viewarticle/936834

Sep 3rd, 2020 - The US Food and Drug Administration (FDA) has approved somapacitan (Sogroya, Novo Nordisk) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).  Somapacitan is a human growth hormone analog. It is admini...

Growth Hormone Deficiency Clinical Practice Guidelines (AACE/ACE, 2019)
https://reference.staging.medscape.com/viewarticle/924401

Jan 31st, 2020 - Guidelines for the management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care were published in 2019 by the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinolo...

Growth Hormone Deficiency Clinical Practice Guidelines (AACE/ACE, 2019)
https://reference.medscape.com/viewarticle/924401

Jan 31st, 2020 - Guidelines for the management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care were published in 2019 by the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinolo...

see more →

Patient Education  1 results see all →